Hangzhou Hospital Staff Cohort

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04910321

Acronym

HHSC

Enrollment

Registered

2021-06-02

Start date

2020-12-30

Completion date

2029-12-31

Last updated

2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Diabetes Mellitus, Metabolic Syndrome

Brief summary

The Hangzhou Hospital Staff Cohort (HHSC) is a prospective cohort study among staffs from three hospitals located in Hangzhou, China, including the Hangzhou First People's Hospital, Hangzhou Women's Hospital, and Hangzhou Red Cross Hospital. Participants recruitment and baseline survey including anthropometric, lifestyle and clinical measurement, as well as biological samples collection are initiated in January 2021. Recruited hospital staff are followed up every year during the medical examination organized by their employer. The primary aim of the HHSC study is to investigate the prospective associations of diet, physical activities, sleep, and other lifestyle factors with the long-term metabolic health of the hospital staffs. The secondary aim of the HHSC study is to integrate multi-omics data including genomics, metabolomics, proteomics and microbiome by a machine learning algorithm, to probe into the complex mediating roles of gene, metabolism and gut microbiota linking lifestyle factors with metabolic health.

Interventions

OTHERdiet, physical activities, sleep

lifestyle factors

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Participants aged 18 years or older * Serving staffs of designated hospitals

Exclusion criteria

* Participants with cancer * Participants with other serious medical disorders

Design outcomes

Primary

Measure	Time frame	Description
Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L	3 years after enrollment	Fasting blood glucose is measured every year during follow-up

Secondary

Measure	Time frame	Description
Change of body mass index	Change from baseline at 3 years	Participants' body weight and height was measured to calculate body mass index every year during follow-up

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026